Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business UpdatePRNewsWire • 03/22/22
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022PRNewsWire • 03/08/22
Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2PRNewsWire • 02/22/22
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat MelanomaPRNewsWire • 01/11/22
Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 ConferencePRNewsWire • 01/03/22
Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual MeetingPRNewsWire • 11/12/21
Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 11/10/21
Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual MeetingPRNewsWire • 10/18/21
Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsPRNewsWire • 10/07/21
Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021PRNewsWire • 09/30/21
Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO PresentationBenzinga • 09/16/21
Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4PRNewsWire • 09/16/21
Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15thPRNewsWire • 09/03/21
Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021PRNewsWire • 08/31/21
Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 08/12/21
Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12thPRNewsWire • 07/07/21
Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12thPRNewsWire • 06/22/21
Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in JunePRNewsWire • 06/14/21
Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic ApproachesPRNewsWire • 06/04/21
Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 05/13/21
Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T CellsPRNewsWire • 05/11/21